Product Pathways - DNA Damage
- Molecular Formula:
- Molecular Weight:
- 281.3 g/mol
Directions for Use
Cycloheximide is supplied as a lyophilized powder. For a 10 mg/ml stock, carefully weigh out and reconstitute 50 mg in 5 ml DMSO or EtOH. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µg/ml for 4-24 hours. Soluble in DMSO, EtOH, or MeOH.
Western blot analysis of extracts from Jurkat cells, untreated (-) , or treated with Cycloheximide (50 μg/ml, 24 hr; +), Bortezomib #2204 (10 nM, 24 hr; +), or both, using Ubiquitin Antibody #3933 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Western blot analysis of extracts from Jurkat cells, untreated (-) or treated with increasing concentrations of Cycloheximide (24 hr), using PARP Antibody #9542 (upper), Cleaved PARP (Asp214) (D64E10) XP® Rabbit mAb #5625 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Cycloheximide is a protein synthesis inhibitor in eukaryotes. Although its precise mechanism of action has yet to be fully elucidated, it has been shown to inhibit translation elongation through binding to the E-site of the 60S ribosomal unit and interfering with deacetylated tRNA (1-3). Although not all cell types are equally sensitive to the apoptosis-inducing effects of cycloheximide, it has been shown to induce cell death in T cells through a FADD-dependent mechanism (4). In addition, cycloheximide and Tumor Necrosis Factor possess a synergistic cytotoxicity (5,6), and consequently they are routinely used together to induce cell death. Investigators have demonstrated that cycloheximide blocks bortezomib-stimulated protein ubiquitination (7).
- Schneider-Poetsch, T. et al. (2010) Nat Chem Biol 6, 209-217.
- Klinge, S. et al. (2011) Science 334, 941-8.
- Pestova, T.V. and Hellen, C.U. (2003) Genes Dev 17, 181-6.
- Tang, D. et al. (1999) J Biol Chem 274, 7245-52.
- Nolop, K.B. and Ryan, U.S. (1990) Am J Physiol 259, L123-9.
- Reid, T.R. et al. (1989) J Biol Chem 264, 4583-9.
- Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.